Skip to main content

Published locations for Rituximab and vemurafenib could challenge frontline chemotherapy for HCL

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Rituximab and vemurafenib could challenge frontline chemotherapy for HCL

User login

  • Reset your password
  • /content/rituximab-and-vemurafenib-could-challenge-frontline-chemotherapy-hcl
  • /hematologynews/article/203623/b-cell-lymphoma/rituximab-and-vemurafenib-could-challenge-frontline
  • /oncologypractice/article/203623/b-cell-lymphoma/rituximab-and-vemurafenib-could-challenge-frontline
  • /hematology-oncology/article/203623/b-cell-lymphoma/rituximab-and-vemurafenib-could-challenge
  • /hematologytimes/article/203623/b-cell-lymphoma/rituximab-and-vemurafenib-could-challenge-frontline
  • /b-cell-lymphoma-icymi/article/203623/b-cell-lymphoma/rituximab-and-vemurafenib-could-challenge